Skip to main content

Table 1 (abstract O33). See text for description

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Start of Study

Year 1

Year 2

Year 3

jLS patient number

50 (100)

44 (88)

39 (78)

37 (74)

Inactive disease

0

19 (38)

21 (42)

24 (48)

Remission off medicine

0

0

0

10 (20)

Disease Flare

NA

11 (22)

10 (20)

6 (12)

Adverse Event ≥ grade 2

NA

21 (42)

12 (24)

7 (14)

PGA-A (IQR)

5 (4-6)

1 (0-2)

0 (0-1.3)

0 (0-1)

mLoSSI (IQR)

7 (4-10)

0 (0-1)

0 (0-0)

0 (0-0)

LSCAM (IQR)

7 (4-13.3)

2 (0-4)

0 (0-2)

0 (0-2)

  1. Numbers shown represent number (%) unless otherwise stated. Median scores are shown. IQR: interquartile range; LSCAM: Localized Scleroderma Cutaneous Activity Measure; mLoSSI: modified Localized Scleroderma Severity Index; NA: not applicable; PGA-A: Physician global assessment of activity